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Chiral 1,5-disubstituted 1,2,3-triazoles – versatile
tools for foldamers and peptidomimetic
applications†
Anna Said Stålsmeden, a Andrew J. Paterson, a Imola Cs. Szigyártó, b
Linda Thunberg, c Johan R. Johansson, *d Tamás Beke-Somfai *b and
Nina Kann *a
1,4- and 1,5-Disubstituted triazole amino acid monomers have gained increasing interest among peptidic
foldamers, as they are easily prepared via Cu- and Ru-catalyzed click reactions, with the potential for side
chain variation. While the latter is key to their applicability, the synthesis and structural properties of the
chiral mono- or disubstituted triazole amino acids have only been partially addressed. We here present
the synthesis of all eight possible chiral derivatives of a triazole monomer prepared via a ruthenium-cata-
lyzed azide alkyne cycloaddition (RuAAC). To evaluate the conformational properties of the individual
building units, a systematic quantum chemical study was performed on all monomers, indicating their
capacity to form several low energy conformers. This feature may be used to effect structural diversity
when the monomers are inserted into various peptide sequences. We envisage that these results will
facilitate new applications for these artificial oligomeric compounds in diverse areas, ranging from phar-
maceutics to biotechnology.
Introduction
The structural and functional properties of natural bio-
molecules can be mimicked by synthetic compounds. Such
man-made molecules can retain the beneficial properties of
their natural counterparts while also benefiting from
additional useful attributes. They can provide increased stabi-
lity against enzymatic degradation,1 better designability, and
diverse side-chain chemistry,2 characteristics that are often
desired for novel bioactive molecules. Consequently, peptido-
mimetics and protein engineering often employ synthetic,
non-natural, amino acid-derived insertions to improve charac-
teristics of natural compounds.3
In the last two decades, it has become apparent that pepti-
dic oligomers containing, or composed almost entirely of,
non-natural amino acids can fold into well-defined secondary
structures, leading to the emerging field of peptidic foldamers,
or foldamers.3c,4 Since the initial studies demonstrating
helical oligomers containing homologated derivatives of
natural amino acids,2,5 a wide variety of compounds have been
investigated in this direction.3c Numerous reports have also
pointed out that these compounds will have a propensity to
fold into secondary structures. Furthermore they can provide
antibacterial,6 antiviral,7 and cell-penetrating activity,8 as well
as having self-assembling properties.9 This may lead to appli-
cations in pharmaceutics or bionanotechnology.
One advantage of constructing foldamers from non-natural
amino acids is that standard techniques for peptide coupling
can be applied for assembling these monomers into a
sequence.3c,10 Such monomers may include synthetic amino
acids based on a cycloalkyl, aromatic or heteroaromatic
scaffold.11 1,4-Disubstituted 1,2,3-triazoles, easily accessible
via the copper-catalyzed azide alkyne cycloaddition (CuAAC)
reaction,12 have also been applied in this context. Examples
include oligo(phenyl-amide-triazole)-type foldamers that func-
tion as halide ion receptors,13 oxazolidinone-triazole units
incorporated into dipeptide mimics for use as foldamer build-
ing blocks.14 as well as other examples of peptide backbone
modifications using 1,4-disubstituted 1,2,3-triazoles.15 In con-
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trast to CuAAC, the ruthenium-catalyzed cycloaddition reaction
(RuAAC) instead provides access to the 1,5-disubstituted 1,2,3-
triazole with a different spatial arrangement of the carboxylic
acid and amino functionality used for linking the monomeric
units.16 Homo- and heterochiral peptidomimetics have been
developed from enantiomerically pure propargylamines and
α-azido acids using the RuAAC reaction.17 NMR and MD simu-
lations have shown the presence of a β-turn-like structure in
homochiral peptido-triazolamers, while a heterochiral triazola-
mer shows a polyproline-like helix. Moreover, a well defined
protocol for the synthesis of chiral propargylamines, with a
side chain in the α-position, is feasible using Ellman’s tert-
butylsulfinamide as a chiral auxiliary.18 The RuAAC reaction
has been frequently utilized in medicinal chemistry appli-
cations,19 including the synthesis of peptidomimetics,20 but
its use in the area of foldamers is as yet very limited. In earlier
reports from our group, we have developed microwave-assisted
methodology for the synthesis of 1,5-disubstituted 1,2,3-tri-
azole monomers via RuAAC and also investigated the struc-
tures and conformations of δ-peptides prepared from these
monomers.21 In addition, we have compared the confor-
mational properties of triazole monomers prepared via CuAAC
and RuAAC.22 In this study, we instead focus on the confor-
mational effects of introducing chiral substituents, on either
side or both sides of the triazole. During the preparation of
this manuscript, a related report, concerning the synthesis of
some 1,5-disubstituted peptidotriazolomers, was published by
Sewald and co-workers.17 While there are some touching
points between the two studies, the present study describes
the complete set of eight possible combinations for mono-
and disubstituted chiral derivatives. Thus, these studies are
different both in terms of the triazoles prepared, as well as
with respect to the computational studies performed. Our
results from these investigations are described herein.
Results and discussion
Monomer synthesis
The chiral alkyne 1 and azide 2 (Fig. 1) used in this study orig-
inate from the amino acid alanine. Employing both enantio-
mers, in combination with the corresponding non-chiral non-
methylated N-Boc propargylamine 3 and methyl 2-azidoacetate
4, allowed the synthesis of eight different stereoisomers of the
triazole derivatives (Fig. 2). The chiral alkynes (R)-1 and (S)-1
were initially prepared via a Bestmann–Ohira reaction23 from
Boc-protected (R)- and (S)-alaninal, where the (R)-enantiomer
was obtained via Dess–Martin oxidation24 of Boc-(R)-alaninol,
and the (S)-form was commercially available. While both
reactions are documented to proceed without causing
racemisation,23,25 we found that erosion of the stereochemistry
had taken place for both enantiomers of 1 in our case. Raines
has reported the preparation of (S)-1 via reduction of the
corresponding Weinreb amide of alanine, followed by a
Bestmann–Ohira reaction of the formed aldehyde in situ, and
this may be a better option to avoid prolonged handling of the
sensitive aldehyde.20b We instead opted for using commer-
cially available (R)-1 and (S)-1 for the continued studies. For
compound 2, both enantiomers were prepared via diazo trans-
fer from the corresponding amine by using 2-azido-1,3-di-
methylimidazolinium hexafluoro-phosphate (ADMP), following
a report by Kitamura et al.26 The non-chiral derivatives 3 and 4
are both commercially available. With all starting materials
in place, reaction conditions for the RuAAC coupling were
then investigated. This involved screening various catalysts,
including the two most commonly used for RuAAC, i.e.
Cp*RuCl(PPh3)2 and Cp*RuCl(COD), as well as [Cp*RuCl2]n
and [Cp*RuCl]4. A solution of (S)-1 and azido ester 4 in THF
was heated to 60 or 80 °C for 20 minutes under microwave con-
ditions, and products were purified by HPLC or flash chrom-
Fig. 1 Chiral and non-chiral alkynes and azides used in this study.
Fig. 2 Chiral 1,5-subsituted triazoles prepared via RuAAC. See
Experimental section for method used.
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atography. The results are shown in Table 1. All the catalysts
screened, with the exception of [Cp*RuCl]4, provided triazole
(S)-5 in moderate to good yields, and showed no significant
differences in enantiomeric excess. The preparation of the full
set of chiral triazoles was then pursued using either Cp*RuCl
(COD) or [Cp*RuCl2]n as the catalyst.
Alkyne (R)-1 was reacted with 4 using 4 mol% [Cp*RuCl2]n
as the catalyst, affording (R)-5, i.e. the enantiomer of the
earlier prepared triazole (S)-5, in a somewhat lower yield
(52%). Conventional heating at 100 °C, using Cp*RuCl(COD)
as the catalyst, was found to be more successful in this case,
affording (R)-5 in 79% yield (Fig. 2) and high enantiomeric
excess (>99%). Subsequently, the (R)- and (S)-enantiomers of
chiral azide 2 were applied and combined with N-Boc-propar-
gylamine 3, yielding the two enantiomers of triazole 6, with
the methyl substituent in the α-position relative to the ester, in
84 and 87% yield respectively. 2D NOESY NMR confirmed the
1,5-regioselectivity of the 1,2,3-triazoles (see ESI†). However,
some loss of stereochemistry was found for compounds (R)-6
and (S)-6, with approximately 10% of the other enantiomer
formed alongside the desired product. As the chiral centre
next to the alkyne 1 remains intact during the reaction, as seen
in Table 1, the cause of this partial racemisation was pin-
pointed to the methyl-substituted carbon of azides 2. To deter-
mine if this racemisation occurs during the synthesis of the
chiral precursor azides 2, or during the RuAAC reaction itself,
azides 2 were subjected to a CuAAC reaction at room tempera-
ture, using CuSO4 as the catalyst (Scheme 1). Both 1,4-triazoles
(R,R)-8 and (S,R)-8 were formed in good yields (92% and 87%
respectively) and good to excellent stereoselectivity, indicating
that the minor loss of stereochemistry is most likely occuring
during the triazole formation itself, rather than in the prepa-
ration of 2. With these results in hand, all four stereoisomers
of the dimethylated triazole 7 (Fig. 2) were prepared in the
same fashion. Azide (R)-2 was first combined with both enan-
tiomers of alkyne 1 to produce the diastereomers (R,R)- and (R,
S)-7 in similar yields as for compounds 6. The same reaction
starting instead from (S)-2 afforded the second set of diastereo-
mers (S,R)- and (S,S)-7 in 95% and 77% yield, respectively.
Interestingly, all these compounds were obtained with excel-
lent enantioselectivity and good to excellent diastereo-
selectivity. The loss of stereochemical integrity for compounds
6 may thus be a result of the lower degree of sterical hindrance
in these compounds, allowing racemisation via enolisation to
take place, while the extra methyl group in compounds 7 may
in some manner block this process. More detailed studies are
needed, however, to elucidate the mechanism for this
racemisation.
Trimer synthesis
To verify that the chiral triazoles prepared could be used for
foldamer synthesis, a trimer was prepared from triazole (S)-5
(Scheme 2). N-Methyl amide (S)-9 was first synthesized via
hydrolysis of (S)-5 with LiOH to the corresponding carboxylic
acid, followed by HATU-mediated amide formation, affording
(S)-9 in 65% yield. A dimer of (S)-5 was then prepared. In one
experiment, (S)-5 was Boc-deprotected with trifluoroacetic acid,
and in a second experiment, (S)-5 was again hydrolyzed with
LiOH. The two parts were then coupled directly without
further purification, using HATU as the coupling agent and
DIPEA as the base, affording dimer (S,S)-10 in 78% yield. (S)-9
was then deprotected and subsequently coupled with hydro-
lysed (S,S)-10, affording trimer (S,S,S)-11 in 46% yield as a white
solid. 2D NOESY NMR was performed on (S,S,S)-11 to study the
conformational properties of the trimer. The 1H–1H NOESY was
recorded at 24 mM concentration in DMSO-d6, using a mixing
time of 500 ms. In comparison to a corresponding non-
chiral trimer reported by us earlier,21 with the N-methyl amide
replaced by a methyl ester, the results are much less conclusive.
Where the non-chiral structure displays a long range coupling
between the Boc tert-butyl group and the terminal methyl group,
i.e. between the two ends of the oligomer, indicating a turn-like
conformer, no such correlation can be seen for (S,S,S)-11. This is
perhaps not surprising, as a greater backbone flexibility would
be expected for the corresponding non-chiral trimer.
Of more interest is a weak short-range coupling between
the triazole CH signals and the methyl substituents on the
chiral carbons in (S,S,S)-11, indicating a twisted conformer
that allows these groups to come into proximity, rather than a
Scheme 1 Chiral 1,4-substituted triazoles prepared via CuAAC.
Table 1 Catalyst evaluation in the RuAAC reaction between (S)-1 and 4
Entry Catalyst Temp. (°C) Yielda (%) eeb (%)
1 Cp*RuCl(PPh3)3 80 42 97.7
2 Cp*RuCl(COD) 60 73 98.4
3 [Cp*RuCl2]n 80 57 97.3
4 [Cp*RuCl]4 80 5 97.5
a Isolated yield. bDetermined by chiral SFC (see ESI† for details).
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structure with a straighter elongated backbone chain.
Excluding expected correlations, no other interactions of inter-
est could be discerned.
Molecular modelling
With the full set of chiral triazoles at hand, our attention was
then directed towards the conformational properties of these
compounds. To explore the conformational properties of the
eight chiral derivatives prepared, quantum chemical (QM) cal-
culations were performed employing three different levels of
theory. QM methods are regularly employed in understanding
structural and energetic properties of non-natural amino acid
compounds. In contrast to natural amino acids and proteins,
proper parametrization of these exotic residues is often
missing, making extensive use of molecular dynamics (MD)
simulations less reliable.27 Previously, the potential energy
hypersurface of an achiral 1,5-disubstituted 1,2,3-triazole
amino acid was explored in an exhaustive scan.22 In the
present study, 20 of these previously found achiral conformers
were employed to construct the eight chiral models, which
resulted the general structure of Ac-5Tzl-NHMe (for more
details see Computational methods, and ESI, Tables S1–S8†).
Since the R and S conformers could be considered enantiomer
pairs, these were tested against the same initial torsional
angles from results of the achiral triazole calculations, and
conformational enantiomers were not considered. This way we
obtained the relative energies for only one side of the asym-
metric potential energy hypersurface (PEHS) for each model,
where those of the enantiomer pairs can be converted into
each other by their inversion center. Therefore the obtained
results are discussed for the enantiomer pairs together.
Considering the (R)-5 and (S)-5 models, respectively, 9 and 7
out of the located 18 and 17 conformers are within 3 kcal
mol−1 in relative energy, counted from the most stable confor-
mer 2′ and 2 (see ESI†). This indicates that in principle both
derivatives have over ten conformers which have low relative
energies and thus could be the structural building units of
several low energy secondary structures. For (R)-6 and (S)-6,
there are 6 and 11, respectively, low energy conformers, i.e.
below 3 kcal mol−1 relative energy, with the most stable confor-
mers being 2 and 1 (see ESI†), respectively. These results indi-
cate that the single substituted models closely resemble to
energetic properties of the achiral triazole derivative where
numerous low-energy secondary structures can be found. In
contrast, for the (R,R)-7 and (S,S)-7 enantiomer pair, there are
only 3 and 5 low energy conformers, with 6 and 1 (see ESI†),
respectively, being the most stable. The (R,S)-7 and (S,R)-7 have
3 and 7 low energy conformers, respectively, with conformers 2
and 2′ as most stable ones (see ESI†). The lower number of
stable conformers for the disubstituted models most likely
originate from steric interactions.
Overall, all chiral compounds have several low energy con-
formers, which may result in conformational diversity when
homo-oligomers are synthesized from these monomers.
Structure and energetics of heptamers
The eight sets of secondary structures were investigated in
order to predict the potentially most preferred structure for
each substitution pattern. To allow formation of defined sec-
ondary structures, longer peptide sequences, heptamers, were
employed. All these sets were investigated in an aqueous
environment, as detailed in the Experimental section under
Scheme 2 Synthesis of trimer (S,S,S)-11.
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Computational methods. These conformations have intra-
molecular hydrogen bonds formed between relevant parts of
the amide groups. Our nomenclature for the conformations is
based on the pseudo-cycles formed by hydrogen bonds, using
the number of atoms in the peptide backbone involved in
forming the H-bond. Thus, conformers H8, H10, H14, and
H16 were investigated for both right (P) and left handed (M)
structures.
When using water as an environment, for (R)-6, (R)-5, and
(R,R)-7, the most preferred secondary structure is the right-
handed H16 conformation, H16P (Fig. 3 and Table S9†) while
the second most stable conformation is H14P. Similarly, due to
being conformational enantiomers, for (S)-6, (S)-5, and (S,S)-7,
the most preferred structure is also H16, but its left handed
form, H16M. For these compounds, the above H16 confor-
mations have a high relative stability compared to the other
investigated secondary structures, as their energy is nearly
9 kcal mol−1 lower than that of the second most stable confor-
mer, H14. Note, that for (R)-5 and (R,R)-7 the H10P is quite
close in relative free energy to H14P. Thus, for these com-
pounds it is very likely that an oligomer with the above chiral
substitution patterns could fold into a helical structure, such
as H16, H14 or H10. In general, when investigating handed-
ness there is a strong preference towards either P or M, as for
(R)-6, and (S)-6, respectively, where the least stable conformer
is H14 for both of them, but with the inverse handedness. For
the (R)-5 and (S)-5 substitution patterns we see a very similar
relative energy distribution, and preference of handedness is
also pronounced because all conformers belonging to the pre-
ferred P, or M subsets have higher or lower relative energies
than its inverse conformer, respectively. For (R,R)-7 and (S,S)-7,
H16 is again the most stable conformer with H14 being the
second most stable one, however, here these conformers have
a somewhat higher stability relative to the other conformers
investigated (Fig. 3).
In contrast to the above six substitution patterns, from a
structural point of view the oligomers built from (S,R)-7 and
(R,S)-7 monomers seem to be the most interesting. In the case
of these two oligomers, the relative energy of the investigated
conformers have values much closer to each other. For (R,S)-7,
the most stable conformer is H10M, however its relative energy
is only ∼3 kcal mol−1 from the second most stable conformer,
H14M (Fig. 4). Furthermore, the third most stable conformer is
H16P, which has the opposite handedness as the above two
conformers, yet its energy is still within 7 kcal mol−1 to that of
H10M. Similarly, in case of (S,R)-7, the same energy distri-
bution can be observed. Based on these results for (S,R)-7, (R,
S)-7 systems, there is probably a steric factor introduced which
renders various secondary structures to comparable stability.
This will probably give rise to a conformational diversity that
is comparable to that observed for natural peptidic com-
pounds in living systems. Note, that for homooligomers, the
Fig. 3 The relative free energies of the investigated secondary structures for hepta-homooligomers using all 8 possible substitution patterns.
Values were obtained at the ωB97X-D/6-31+G(d,p)//ωB97X-D/6-31G(d) level of theory using water as solvent and involving entropy contributions as
well as zero point and thermal energy corrections. Relative values were determined for each peptide using the average energy value of all secondary
structures as reference point. For more details, see section Computational methods.
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above results are in contrast to the conformational diversity
observed for monomeric compounds. Once the monosubsti-
tuted Tzl amino acids are oligomerized, there is a clear prefer-
ence for one secondary structure among the ones investigated.
This observation is also valid for disubstituted compounds
with both substitutions having the same chirality, (S,S)-7 and
(R,R)-7. In contrast to the above, the mixed substitution pat-
terns, (S,R)-7 and (R,S)-7, may result in conformational diver-
sity for homooligomeric foldamers as several secondary struc-
ture elements have close relative energies, irrespective of
handedness.
Conclusions
The complete set of possible chiral combinations for 1,5-di-
substituted 1,2,3-triazole units have been prepared via a ruthe-
nium-catalyzed azide alkyne cycloaddition (RuAAC), in moder-
ate to good yields. These chiral monomeric triazole building
blocks are intended for applications in the area of foldamer
synthesis. The precursor alkynes and azides used for the
RuAAC reaction all originate from the amino acids glycine and
alanine. To demonstrate the applicability of the 1,5-triazole
monomer building blocks in the synthesis of foldamers, a
trimer structure was also prepared. A conformational and
structural investigation of these monomers was then carried
out to predict the effect of introducing these units into a folda-
mer. Computational studies on the monomers indicate that
several low energy conformers are present for all eight com-
pounds, where several secondary structures may be built with
low relative energies for peptidic molecules containing these
compounds as single insertions. This is especially indicated
for the monosubstituted compounds, where the number of
lower energy conformers exceeds ten. However, when consider-
ing homooligomer foldamers built from these compounds,
relative energies show a single most stable conformer for 6 out
of the 8 substitution patterns. The only two exceptions are
(R,S) and (S,R), where several secondary structures result in
relative energies very close to each other, indicating that struc-
tural diversity of the backbone, as a key feature for fine-tuning
structural properties with various side chain patterns, is
present. Overall, we anticipate that the outcome of these
studies can be of use in the design and synthesis of new




Starting materials were purchased from commercial sources
unless otherwise stated. All reactions were performed under an
inert atmosphere (argon or nitrogen). Chiral alkynes 1 were
initially synthesized from commercial Boc-(R)-alaninol and
Boc-(S)-alaninal in one or two steps, but were subsequently
purchased from Ark Pharm Inc. (tert-butyl (S)-but-3-yn-2-yl-car-
bamate, 99.5% ee) and J&W PharmLab LLC (tert-butyl (R)-but-
3-yn-2-ylcarbamate, 98.8% ee). THF was purchased as anhy-
drous grade. Automated flash chromatography was performed
on a Biotage Isolera One. 1H, 13C and 2D NOESY NMR were
acquired on a Varian MR 400 MHz instrument or on a Bruker
Avance III 500 MHz spectrometer fitted with a cryoprobe in
CDCl3 or DMSO, using residual solvent peaks for reference.
FTIR was performed on a PerkinElmer Frontier FTIR
Spectrometer with an ATR device using Spectrum software.
The enantiomeric excess was determined by chiral SFC,
using a Chiralpak IC column (25% EtOH in CO2) or a Lux
Cellulose-5 column (25% EtOH in CO2) or a Lux Amylose-1
column (10% EtOH in CO2) at 120 bar, 40 °C, flow rate 3.5 mL
min−1, 220 nm detection (see ESI† for chromatographic data
for each compound).
Experimental procedures
Synthesis of chiral propargylic amines
tert-Butyl (R)-but-3-yn-2-ylcarbamate ((R)-1). Alkyne (R)-1 was
prepared via oxidation of N-Boc-D-alaninol ((R)-2-(Boc-amino)-
1-propanol) to N-Boc-D-alaninal, followed by a Bestmann–
Ohira reaction to afford (R)-1. Oxidation: To a solution of
N-Boc-D-alaninol (146 mg, 0.833 mmol) in CH2Cl2 (15 mL) was
added Dess–Martin periodinane (429 mg, 1.01 mmol) in one
portion. The reaction mixture was stirred at ambient tempera-
ture for 2.5 h and then extracted with EtOAc (20 mL). After
phase separation, the organic phase was washed with 2 M
NaHSO3 (5 mL) and the aqueous phase was extracted with
EtOAc (3 × 10 mL). The combined organic phases were washed
with 1 M NaOH (15 mL) and brine (10 mL), then dried
Fig. 4 The three most stable conformation of (S,R)-7 heptahomooligo-
mer. Calculations were performed at the ωB97X-D/6-31+G(d,p)//
ωB97X-D/6-31G(d) level of theory.
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(Na2SO4) and concentrated to afford N-Boc-D-alaninal (138 mg,
91%) as a white solid of approximately 95% purity. 1H and 13C
NMR data were in accordance with published data for this
compound.28 This aldehyde was used directly in the next step
without further purification. Bestmann–Ohira reaction: To a
solution of N-Boc-D-alaninal (253 mg, 1.46 mmol) in MeOH
(25 mL) was added K2CO3 (404 mg, 2.92 mmol) in one portion.
The reaction was stirred at ambient temperature for 4 h. The
solution was concentrated by rotary evaporation and water
(25 mL) and EtOAc (25 mL) were added. After phase separ-
ation, the aqueous phase was further extracted with EtOAc (3 ×
25 mL) and the combined organic phases washed with brine
(25 mL), dried (Na2SO4) and concentrated. Flash chromato-
graphy (silica gel, eluent: CH2Cl2) afforded 143 mg of (R)-1 as a
white solid. 1H and 13C NMR data were in accordance with
published data for this compound.29 However, the ee of (R)-1
was found to be 13.4%. For further studies, compound (R)-1
was instead purchased from J&W PharmLab (ee 98.8%).
tert-Butyl (S)-but-3-yn-2-ylcarbamate ((S)-1). Alkyne (S)-1 was
prepared via a Bestmann–Ohira reaction of N-Boc-D-alaninal
using the same procedure as for (R)-1. 1H and 13C NMR data
were in accordance with published data for this compound.30
However, the ee of (S)-1 was found to be 25.8%. For further
studies, compound (S)-1 was thus instead purchased from Ark
Pharm Inc. (ee 98.5%).
Synthesis of chiral azides
Methyl (R)-2-azidopropanoate ((R)-2). NOTE: This is a small-
molecule azide and should be handled with care. This reaction
should not be scaled up. Do not apply heat to the neat azide
product and any reaction with it should be diluted at least 10
times. (R)-Methyl 2-aminopropanoate·HCl (855 mg, 6.0 mmol)
was suspended in anhydrous acetonitrile (10 mL) and diethyl-
amine (3.0 mL, 28.7 mmol) was added. A suspension of
2-azido-1,3-dimethyl-4,5-dihydro-1H-imidazol-3-ium hexa-
fluorophosphate (ADMP) (2.07 g, 7.26 mmol) in anhydrous
acetonitrile (10 mL) was added dropwise at 23 °C over 10 min
(during the addition, the temperature increased to 32 °C). The
reaction mixture was stirred ambient temperature for 1 h, then
quenched with saturated NaHCO3 (15 mL) and stirred for
10 min. CH2Cl2 (20 mL) and water (5 mL) was added. After
phase separation, the aqueous layer was extracted with CH2Cl2
(3 × 5 mL). The combined organic layers were filtered through
a phase separator (Telos) and concentrated under reduced
pressure. The crude product was purified by gel filtration
through silica gel (25 g), eluting with CH2Cl2. Concentration of
this solution under reduced pressure afforded the product as a
colourless oil (351 mg, 45%).1H NMR (500 MHz, DMSO): δ
4.33 (q, J = 7.1 Hz, 1H), 3.72 (s, 3H), 1.34 (d, J = 7.1 Hz, 3H);
13C NMR (126 MHz, DMSO) δ 171.20, 56.64, 52.52, 16.48. This
compound has been reported earlier,31 using a different pre-
parative procedure. Due to the sensitivity of this azide, the ee
was not determined at this stage.
Methyl (S)-2-azidopropanoate ((S)-2). Procedure as for (R)-2
(340 mg, 43%). 1H NMR (500 MHz, DMSO) δ 4.33 (q, J = 7.1
Hz, 1H), 3.72 (s, 3H), 1.34 (d, J = 7.1 Hz, 3H); 13C NMR
(126 MHz, DMSO) δ 171.20, 56.64, 52.52, 16.48. This com-
pound has been reported earlier, using a different preparative
procedure.32 Due to the sensitivity of this azide, the ee was not
determined at this stage.
General procedure for the RuAAC reaction
RuAAC reactions were performed using microwave heating
(Method A) or conventional oil bath heating (Method B).
Method A: The corresponding alkyne (0.44 mmol) and azide
(0.44 mmol) were charged in a Biotage microwave vial with a
stirrer bar and dissolved in anhydrous THF (3 mL). Cp*RuCl
(COD) (8.4 mg, 0.02 mmol) was added and the vial was sealed,
evacuated and refilled with nitrogen three times. The reaction
mixture was then heated to 60 °C for 20 min in a microwave
reactor or heated in an oil bath at 100 °C for 15 h. The result-
ing solution was filtered through a syringe filter and concen-
trated. The crude product was purified by preparative HPLC on
a Kromasil C8 column (10 μm 250 × 20 ID mm), using a gradi-
ent of 5–45% acetonitrile in a H2O/acetonitrile/formic acid (95/
5/0.2) buffer, over 20 minutes with a flow rate of 19 mL min−1.
The compounds were detected by UV at 225 nm. Pure fractions
were combined and lyophilized to obtain the product.
Method B, exemplified by the formation of (S)-6: To a micro-
wave vial equipped with a stirrer bar was added methyl (S)-2-
azidopropanoate (26 mg, 0.2 mmol) and N-Boc-propargyla-
mine (34 mg, 0.2 mmol) along with Cp*RuCl(COD) (3.5 mg,
0.009 mmol) and THF (1 mL). The vessel was sealed in an
argon atmosphere and stirred at 100 °C for 15 h or until crude
TLC analysis indicated no more starting materials were being
consumed (visualized by staining with ninhydrin solution and
heating). The crude product was purified by automated flash
chromatography on a Biotage Isolera One system, using a gra-
dient of 30–60% EtOAc in petroleum ether. Pure fractions were
combined and concentrated by rotary evaporation to afford the
product.
Methyl (R)-2-(5-(1-((tert-butoxycarbonyl)amino)ethyl)-1H-
1,2,3-triazol-1-yl)acetate ((R)-5). Prepared from (R)-1 and 4,
affording (R)-5 as a brown solid (method A: 66 mg, 52%, ee
99.1%; method B: 45 mg, 79%; ee 99.1%); [α]D +28.1 (c 1.1 in
CH2Cl2); νmax (neat) 2979, 1753, 1698, 1517, 1453, 1367, 1304,
1243, 1167, 1058, 986, 859, 706; 1H NMR (400 MHz, CDCl3):
δ 7.53 (s, 1H, triazole-CH), 5.32–5.19 (m, 2H, CH2), 4.92–4.80
(m, 1H, CHCH3), 4.88 (br s, 1H, NH), 3.74 (s, 3H, OCH3), 1.53
(d, J = 7.0 Hz, 3H, CHCH3), 1.37 (s, 9H, C(CH3)3);
13C NMR
(100 MHz, CDCl3): δ 167.20, 154.91, 140.09, 131.53, 80.33,
52.84, 49.06, 40.07, 28.19, 20.27; HRMS (ESI+): found 285.1578
[M + H]+; C12H21N4O4 requires 285.1563.
Methyl (S)-2-(5-(1-((tert-butoxycarbonyl)amino)ethyl)-1H-
1,2,3-triazol-1-yl)acetate ((S)-5). Prepared from (S)-1 and 4,
affording (S)-5 as a brown solid (method A: 92 mg, 73%, ee
98.4%; method B: 42 mg, 74%, ee 98.4%); [α]D −28.6 (c 0.925
in CH2Cl2); νmax (neat) 2980, 1752, 1698, 1513, 1453, 1392,
1304, 1239, 1160, 1058, 986, 859, 704; 1H NMR (400 MHz,
CDCl3): δ 7.58 (s, 1H, triazole-CH), 5.24–5.37 (m, 2H, CH2),
4.87–4.95 (m, 1H, CHCH3), 4.76 (br s, 1H, NH), 3.78 (s, 3H,
OCH3), 1.58 (d, J = 6.9 Hz, 3H, CHCH3), 1.41 (s, 9H, C(CH3)3);
Organic & Biomolecular Chemistry Paper


























































































13C NMR (100 MHz, CDCl3): δ 167.22, 154.91, 140.08, 131.56,
80.42, 52.87, 49.10, 40.09, 28.22, 20.33; HRMS (ESI+): found
285.1581 [M + H]+; C12H21N4O4 requires 285.1563.
Methyl (R)-2-(5-(((tert-butoxycarbonyl)amino)methyl)-1H-
1,2,3-triazol-1-yl)propanoate ((R)-6). Prepared from (R)-2 and 3,
using method A, affording (R)-6 as a pale yellow oil (186 mg;
84%; ee 81.8%); [α]D +12.2 (c 0.975 in CH2Cl2); νmax (neat) 2978,
1749, 1749, 1703, 1514, 1449, 1392, 1366, 1247, 1165, 1110,
1079, 1019, 978, 930, 858, 757, 658; 1H NMR (500 MHz, DMSO-
d ): δ 7.54 (s, 1H, triazole-CH), 7.44 (br s, 1H, triazole-CH), 5.61
(q, J = 7.2 Hz, 1H, CHCH3), 4.18–4.28 (m, 2H, CH2), 3.66 (s, 3H,
OCH3), 1.76 (d, J = 7.2 Hz, 3H, CHCH3), 1.37 (s, 9H, C(CH3)3);
13C NMR (126 MHz, DMSO-d ): δ 169.45, 155.55, 136.37, 132.39,
78.44, 55.10, 52.77, 32.55, 28.09, 16.90; HRMS (ESI+): found
285.1557 [M + H]+; C12H21N4O4 requires 285.1563.
Methyl (S)-2-(5-(((tert-butoxycarbonyl)amino)methyl)-1H-
1,2,3-triazol-1-yl)propanoate ((S)-6). Prepared from (S)-2 and 3,
using method A, affording (S)-6 as a pale yellow oil (173 mg;
87%; ee 79.2%); [α]D = −14 (c 1.1 in CH2Cl2); νmax (neat) 2978,
1748, 1698, 1506, 1449, 1367, 1246, 1165, 1079, 1020; 1H NMR
(400 MHz, DMSO-d ): δ 7.57 (s, 1H, triazole-CH), 5.54–5.35 (m,
1H, CHCH3), 5.11 (s, 1H, NH), 4.54–4.27 (m, 2H, CH2), 3.72 (s,
3H, OCH3), 1.91 (d, J = 7.3 Hz, 3H, CHCH3), 1.42 (s, 9H,
C(CH3)3);
13C NMR (100 MHz, CDCl3): δ 169.66, 155.70, 135.28,
133.51, 80.57, 56.31, 53.21, 33.17, 28.36, 28.36, 17.07; HRMS
(ESI+): found 285.1556 [M + H]+; C12H21N4O4 requires
285.1563.
Methyl (R)-2-(5-((R)-1-((tert-butoxycarbonyl)amino)ethyl)-1H-
1,2,3-triazol-1-yl)propanoate ((R,R)-7). Prepared from (R)-1 and
(R)-2, using method B, affording (R,R)-7 as a brown solid
(50 mg; 84% yield; dr >99/1; ee >99%); [α]D +0.59 (c 1.3 in
CH2Cl2); νmax (neat) 3206, 2982, 1753, 1698, 1500, 1448, 1436,
1383, 1367, 1344, 1307, 1265, 1249, 1160, 1135, 1117, 1081,
1060, 1021, 976, 856, 834, 732, 703, 663, 636, 556, 513, 471, 418;
1H NMR (400 MHz, CDCl3): 7.57 (s, 1H, triazole CH), 5.31 (q, J =
5.7 Hz, 1H, COCHCH3), 5.02–4.90 (m, 1H, NHCH), 4.69 (d, J =
8.2 Hz, 1H, NH), 3.72 (s, 3H, OCH3), 1.95 (d, J = 7.3 Hz, 3H) and
1.58 (d, J = 6.8 Hz, 3H, COCHCH3), 1.41 (s, 9H, C(CH3)3);
13C
NMR (100 MHz, CDCl3): δ 169.97, 154.89, 138.99, 131.69, 80.54,
56.19, 53.15, 40.20, 28.40, 20.56, 17.60; HRMS (ESI+): found
299.1732 [M + H]+; C13H23N4O4 requires 299.1719.
Methyl (R)-2-(5-((S)-1-((tert-butoxycarbonyl)amino)ethyl)-1H-
1,2,3-triazol-1-yl)propanoate ((R,S)-7). Prepared from (S)-1 and
(R)-2, using method B, affording (R,S)-7 as a pale brown solid
(52 mg; 87%; dr >93/7, ee >99%); [α]D −0.22 (c 0.8 in CH2Cl2;
νmax (neat) 3322, 2979, 1750, 1696, 1514, 1451, 1367, 1305,
1246, 1213, 1162, 1118, 1079, 1057, 1024, 976, 859, 761, 705,
659; 1H NMR (400 MHz, CDCl3): 7.57 (s, 1H, triazole-CH), 5.55
(q, J = 5.3 Hz, 1H, COCHCH3), 5.00–4.89 (m, 1H, NHCH), 4.78
(d, J = 7.8 Hz, 1H, NH), 3.72 (s, 3H, –OCH3), 1.91 (d, J = 7.1 Hz,
3H) and 1.57 (d, J = 6.9 Hz, 3H, COCHCH3), 1.41 (s, 9H,
C(CH3)3);
13C NMR (100 MHz, CDCl3): 169.60, 155.00, 140.22,
131.29, 80.65, 56.04, 53.17, 40.08, 28.39, 20.53, 16.83; HRMS
(ESI+): found 299.1735 [M + H]+; C13H23N4O4 requires 299.1719.
Methyl (S)-2-(5-((R)-1-((tert-butoxycarbonyl)amino)ethyl)-1H-
1,2,3-triazol-1-yl)propanoate ((S,R)-7). Prepared from (R)-1 and
(S)-2, using method B, affording (S,R)-7 as a pale brown solid
(56 mg; 95%; dr 96/4, ee >99%); [α]D +0.23 (c 1.05 in CH2Cl2;
νmax (neat) 3329, 2979, 1750, 1699, 1517, 1452, 1367, 1306,
1247, 1166, 1118, 1079, 1058, 1025, 976, 859, 761, 660; 1H
NMR (400 MHz, CDCl3): δ 7.55 (s, 1H, triazole-CH), 5.69–5.40
(m, 1H, COCHCH3), 4.92 (bra app s, 2H, NHCH and NH), 3.70
(s, 3H, OCH3), 1.89 (d, J = 7.2 Hz, 3H) and 1.62–1.50 (m, 3H,
COCHCH3), 1.40 (s, 9H, C(CH3)3);
13C NMR (100 MHz, CDCl3):
169.57, 155.01, 140.21, 131.24, 80.53, 55.98, 53.12, 40.03,
28.33, 20.46, 16.79; HRMS (ESI+): found 299.1728 [M + H]+;
C13H23N4O4 requires 299.1719.
Methyl (S)-2-(5-((S)-1-((tert-butoxycarbonyl)amino)ethyl)-1H-
1,2,3-triazol-1-yl)propanoate ((S,S)-7). Prepared from (S)-1 and
(S)-2, using method B, affording (S,S)-7 as a light brown solid
(46 mg; 77%; dr >99/1; ee 98.8%); [α]D −0.71 (c 0.925 in
CH2Cl2); νmax (neat) 3055, 2983, 1751, 1702, 1499, 1451, 1382,
1368, 1306, 1265, 1160, 1118, 1079, 1058, 1021, 975, 896, 858,
835, 731, 702, 555; 1H NMR (400 MHz, CDCl3): δ 7.57 (s, 1H,
triazole-CH), 5.31 (q, J = 7.0 Hz, 1H, COCHCH3), 4.97 (dt, J =
13.3, 6.2 Hz, 1H, NHCH), 4.67 (br s, 1H, NH), 3.72 (s, 3H,
OCH3), 1.95 (d, J = 7.3 Hz, 3H) and 1.58 (d, J = 6.8 Hz, 3H,
COCHCH3), 1.42 (s, 9H, C(CH3)3);
13C NMR (100 MHz, CDCl3):
δ 169.97, 154.87, 138.98, 131.69, 80.54, 56.19, 53.16, 40.22,
28.40, 20.56, 17.60; HRMS (ESI+): found 299.1725 [M + H]+;
C13H23N4O4 requires 299.1719.
General procedure for the CuAAC reaction
To a Biotage microwave vial equipped with a stirrer bar was
added the corresponding azide (26 mg, 0.2 mmol) and alkyne
(34 mg, 0.2 mmol) along with CuSO4·5H2O (1 mg,
0.004 mmol), sodium ascorbate (2.5 mg, 0.012 mmol) and a
1 : 1 mixture of H2O : tBuOH (1 mL). The vessel was sealed in
an air atmosphere and stirred at room temperature for 20 h at
which point TLC analysis indicated the reaction was complete.
The crude reaction mixture was then diluted in CH2Cl2
(10 mL) and water (10 mL) and the aqueous layer was extracted
a further two times with CH2Cl2 (2 × 10 mL). The combined
organic fractions were then washed with brine (10 mL) and
dried using MgSO4. The MgSO4 was then removed from the
organic fractions by filtration, concentrated, and purified by
flash column chromatography (40–60% EtOAC/hexane) to
afford the pure products.
Methyl (R)-2-(4-((R)-1-((tert-butoxycarbonyl)amino)ethyl)-1H-
1,2,3-triazol-1-yl)propanoate ((R,R)-8). Prepared from (R)-1 and
(R)-2, affording (R,R)-8 as an oil (55 mg; 92%; dr >99/1; ee
89.8%); [α]D +20.2 (c 1.0 in CH2Cl2); νmax (neat) 2978, 2155,
1749, 1699, 1515, 1450, 1366, 1244, 1166, 1095, 1047, 860, 780;
1H NMR (400 MHz, CDCl3) δ 7.59 (s, 1H), 5.42 (q, J = 7.4 Hz,
1H), 5.13 (s, 1H), 4.93 (dq, J = 7.5, 6.2 Hz, 1H), 3.74 (s, 3H),
1.79 (d, J = 7.3 Hz, 3H), 1.54 (d, J = 6.9 Hz, 3H), 1.41 (s, 9H);
13C NMR (101 MHz, cdcl3) δ 169.80, 155.20, 150.10, 119.93,
79.58, 58.11, 53.14, 43.01, 28.43, 21.35, 18.25. HRMS (ESI+):
found 299.1725 [M + H]+; C13H23N4O4 requires 299.1719.
Methyl (S)-2-(4-((R)-1-((tert-butoxycarbonyl)amino)ethyl)-1H-
1,2,3-triazol-1-yl)propanoate ((S,R)-8). Prepared from (R)-1 and
(S)-2, affording (R,S)-8 as an oil (52 mg; 87%; dr >99/1; ee
Paper Organic & Biomolecular Chemistry


























































































99.4%); [α]D +50.4 (c 0.5 in CH2Cl2); νmax (neat) 2978, 1749,
1702, 1516, 1454, 1366, 1246, 1169, 1048; 1H NMR (400 MHz,
CDCl3) δ 7.58 (s, 1H), 5.42 (q, J = 7.4 Hz, 1H), 5.13 (br s, 1H),
4.92 (dq, J = 8.1, 7.6 Hz, 1H), 3.73 (s, 3H), 1.79 (d, J = 7.3 Hz,
3H), 1.54 (d, J = 6.9 Hz, 3H), 1.41 (s, 9H); 13C NMR (101 MHz,
CDCl3) δ 169.79, 155.22, 150.22, 119.93, 119.90, 79.60, 58.12,
53.14, 43.01, 28.44, 21.32, 18.26. HRMS (ESI+): found 299.1713
[M + H]+; C13H23N4O4 requires 299.1719.
tert-Butyl (S)-(1-(1-(2-(methylamino)-2-oxoethyl)-1H-1,2,3-
triazol-5-yl)ethyl)carbamate ((S)-9). To a microwave vial
equipped with a stirrer bar was added (S)-5 (56 mg, 0.2 mmol)
and MeOH (2 mL). 1 M LiOH (0.6 mL, 0.6 mmol) was then
added dropwise and the solution was stirred at rt for 1.5 h.
Water (5 mL) was then added and 1 M HCl (0.6 mL, 0.6 mmol)
was added dropwise with stirring. The mixture was transferred
to a separating funnel and extracted with CH2Cl2 (4 × 5 mL).
The combined organic phases were passed through a TELOS
phase separator. The solvent was then removed under a
reduced pressure and the resulting carboxylic acid was trans-
ferred to a microwave vial equipped with stirrer bar and dis-
solved in CH2Cl2 (2 mL). Methylammonium chloride (54 mg,
0.8 mmol) was then added followed by DIPEA (209 µL,
1.2 mmol). HATU (80 mg, 0.21 mmol) was then added, and the
vessel was sealed and allowed to react over night at rt. The
reaction mixture was then transferred to a separating funnel
along with aq. sat. NH4Cl (5 mL) and was extracted with EtOAc
(4 × 5 mL). The combined organic phases were dried using
MgSO4, concentrated, and purified by flash column chromato-
graphy eluting with 80–100% EtOAc/hexane to afford (S)-9 as a
white solid (37 mg, 65% yield). A second chromatography step
was sometimes necessary to remove impurities deriving from
the coupling reagent. [α]D −2.1 (c 0.75 in CH2Cl2); νmax (neat)
3340, 3318, 2986, 2937, 1676, 1643; 1H NMR (400 MHz, CDCl3)
δ 7.62 (s, 1H), 6.15 (s, 1H), 5.21 (d, J = 16.7 Hz, 1H), 5.03 (d, J =
16.5 Hz, 1H), 4.97–4.81 (m, 2H), 2.81 (d, J = 4.8 Hz, 3H), 1.55
(d, J = 6.7 Hz, 3H), 1.41 (s, 9H); 13C NMR (101 MHz, CDCl3)
δ 165.74, 154.95, 140.70, 131.60, 80.65, 51.02, 40.66, 28.24,
26.46, 20.65. HRMS (ESI+): found 284.1729 [M + H]+;
C12H22N5O3 requires 284.1722.
Synthesis of dimer (S,S)-10
Boc-deprotection of (S)-5. To a microwave vial equipped with
a stirrer bar was added (S)-5 (56 mg, 0.2 mmol) and CH2Cl2
(0.2 mL). Trifluoracetic acid (TFA) (0.1 mL) was then added
and the reaction was stirred at rt for 1.5 h. The reaction
mixture was then concentrated under a stream of nitrogen and
the salt was used directly for the amide coupling reaction.
Hydrolysis of (S)-5. To a microwave vial equipped with a
stirrer bar was added (S)-5 (56 mg, 0.2 mmol) and MeOH
(2 mL). 1 M LiOH (0.6 mL, 0.6 mmol) was then added drop-
wise and the solution was stirred at rt for 1.5 h. Deionised
water (5 mL) was then added and 1 M HCl (0.6 mL, 0.6 mmol)
was added dropwise with stirring. The mixture was transferred
to a separating funnel and extracted with CH2Cl2 (4 × 5 mL).
The combined organic phases were passed through a TELOS
phase separator. The solvent was then removed under reduced
pressure and the resulting carboxylic acid was used directly in
the amide coupling reaction.
Amide coupling reaction. To a microwave vial equipped with
a stirrer bar was added the Boc-deprotected (S)-5 and the car-
boxylic acid formed by hydrolysis of (S)-5, together with
CH2Cl2 (4 mL). DIPEA (140 µL, 0.8 mmol) was then added fol-
lowed by HATU (80 mg, 0.21 mmol). The vessel was sealed and
allowed to react overnight at rt. The reaction mixture was then
transferred to a separating funnel along with aqueous satu-
rated NH4Cl (5 mL) and extracted with EtOAc (4 × 5 mL). The
combined organic phases were passed through a TELOS phase
separator, concentrated, and purified by flash column chrom-
atography eluting with 80–100% EtOAc/hexane. The crude
white solid was then further purified by trituration using
hexane and dried to yield dimer (S,S)-10 as a white solid
(68 mg, 78% yield). [α]D −33.0 (c 0.1 in CH2Cl2); νmax (neat)
3311 (br), 2986, 1749, 1672, 1535, 1523; 1H NMR (400 MHz,
CDCl3) δ 7.60 (s, 1H), 7.56 (s, 1H), 7.41 (d, J = 8.2 Hz, 1H), 5.43
(d, J = 17.7 Hz, 1H), 5.33 (d, J = 17.6 Hz, 1H), 5.20–5.07 (m,
2H), 5.07 (d, J = 7.2 Hz, 1H), 4.90 (d, J = 16.6 Hz, 1H), 4.73 (p, J
= 7.0 Hz, 1H), 3.77 (s, 3H), 1.57 (d, J = 7.0 Hz, 3H), 1.47 (d, J =
6.9 Hz, 3H), 1.41 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 167.66,
165.27, 155.49, 141.10, 140.05, 132.04, 131.47, 81.02, 53.13,
50.79, 49.41, 41.13, 39.20, 28.43, 20.76, 19.78. HRMS (ESI+):
found 437.2248 [M + H]+; C18H29N8O5 requires 437.2261.
Synthesis of trimer (S,S,S)-11
Boc-deprotection of (S)-9. To a microwave vial equipped with
a stirrer bar was added (S)-9 (28 mg, 0.1 mmol) and CH2Cl2
(2 mL). TFA (1 mL) was then added and the reaction mixture
was stirred at rt for 1.5 h. The reaction mixture was then con-
densed under a stream of nitrogen and the salt was used
directly in the amide coupling reaction.
Hydrolysis of (S,S)-10. To a microwave vial equipped with
stirrer bar was added (S,S)-10 (44 mg, 0.1 mmol) and MeOH
(1 mL). 1 M LiOH (0.3 mL, 0.3 mmol) was then added dropwise
and the solution was stirred at rt for 1.5 h. Deionised water
(5 mL) was then added and 1 M HCl (0.3 mL, 0.3 mmol) was
added dropwise with stirring. The mixture was transferred to a
separating funnel and extracted with EtOAc (4 × 10 mL). The
combined organic layers were passed through a TELOS phase
separator. The solvent was then removed under a reduced
pressure and the resulting carboxylic acid was used directly.
Amide coupling reaction. To a microwave vial equipped with
stirrer bar was added the Boc-deprotected (S)-9 and the car-
boxylic acid formed by hydrolysis of (S,S)-10, together with
DMF (1 mL). DIPEA (70 µL, 0.4 mmol) was then added, fol-
lowed by HATU (39 mg, 0.105 mmol). The vessel was sealed
and the reaction was allowed to react overnight at rt. The DMF
was removed and the crude reaction mixture was purified
directly by flash column chromatography eluting with a gradi-
ent of 5–15% MeOH/CH2Cl2. The crude white solid was then
further purified by trituration using CHCl3, followed by 1 M
NaOH and H2O, before being dried, affording trimer (S,S,S)-11
as a white solid (27 mg, 46% yield). [α]D −9.8 (c 0.22 in
CH2Cl2); νmax (neat) 3303 (br), 2983, 1749, 1669 (br), 1537;
Organic & Biomolecular Chemistry Paper


























































































1H NMR (400 MHz, DMSO-d6) δ 8.93 (d, J = 7.6 Hz, 2H), 8.20
(q, J = 4.6 Hz, 1H), 7.73 (s, 1H), 7.72 (s, 1H), 7.57 (s, 1H), 7.45
(d, J = 8.0 Hz, 1H), 5.20–4.96 (m, 7H), 4.92 (p, J = 7.0 Hz, 1H),
4.62 (dt, J = 15.3, 6.6 Hz, 1H), 2.60 (d, J = 4.6 Hz, 3H), 1.45 (d, J
= 6.9 Hz, 3H), 1.41 (d, J = 7.0 Hz, 3H), 1.32 (s, 9H), 1.27 (d, J =
7.0 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) δ 165.71, 165.13,
165.05, 154.98, 141.60, 140.52, 140.29, 131.8, 131.05, 130.70,
78.36, 49.83, 49.65, 49.53, 40.30 (overlaps with DMSO), 38.82,
38.75, 28.10, 25.59, 20.17, 19.77, 19.70; HRMS (ESI+): found
588.3096 [M + H]+; C24H38N13O5 requires 588.3119.
Computational methods
All computations were carried out using the Gaussian 09 soft-
ware package.33 In contrast to experiments, for the calculations
the monomer amino acids had N-methyl and acetamide protect-
ing groups at their C- and N-terminals, respectively, abbreviated
as Ac-5Tzl-NHMe. In case of the longer models the C-terminal
protecting group was NH2, resulting the general Ac-(5Tzl)7-NH2
form. Nevertheless, the same nomenclature was applied for the
substitution patterns as for the experiments (Fig. 2). For the
monomers, the 27 minima obtained previously in an exhaustive
conformational search for the achiral models at the RHF/3-21G
level of theory,22 were employed in the current study as initial
conformations. Out of these 7 starting conformers were comple-
tely planar, with relative energies of their achiral version higher
than 20 kcal mol−1. Consequently, these were omitted for the
current chiral models, leaving 20 starting test conformers for all
eight models. The total of 160 optimisations were primarily per-
formed at the RHF/3-21G level of theory. Further on, the opti-
mised structures were submitted to calculations using Becke’s
three parameter functional with the Lee–Yang–Parr exchange
functional (B3LYP),34 the ωB97X-D functional by Chai and
Head-Gordon,35 which included dispersion correction and long-
range electron correlation corrections, as well as M06-2X func-
tional developed by Zhao and Truhlar.36 For all functionals, the
6-311++G(2d,2p) basis set was employed. The obtained results
for all the conformers are found in the ESI.†
To estimate secondary structure preference of longer oligo-
mers composed of the investigated 8 monomers, previously
defined secondary structures were employed.21 Initially, five
secondary structures, four helical, and one extended, were
modified with the 8 chiral substitution patterns and optimised
at the ωB97x-D/6-31G(d) level of theory. To predict preference
of helicity handedness, both P and M helices were optimised
resulting a total of 9 secondary structures. Considering the
large size and the unfavorable nature of the extended confor-
mation, for many substitution patterns this conformer experi-
enced convergence problems during the calculations, therefore
this conformer was excluded from further investigation. To
validate the critical points, i.e. to confirm that they are local
minima, as well as to obtain zero point and thermal correc-
tions to the energy, and entropy contributions to provide
Gibbs free energy values, normal mode analysis was performed
on the obtained conformers at the ωB97x-D/6-31G(d) level of
theory. These optimised conformers were also submitted to
point energy calculations employing the same functional and
the 6-31+G(d,p) basis set. Further on, environmental effects of
water were considered also by single point energy calculations
at the samel level of theory, using the implicit solvent model
integral equation formalism for polarizable continuum model
(IEFPCM) (Tables S1–S9†).
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